Á¦¸ñ [´º½º] Consequences of Delaying, Denying, Limiting, or Refusing FDA Drug Firm Inspection. ³¯Â¥ 2014-10-28
  ±Û¾´ÀÌ K-GMP Á¶È¸¼ö 1,377
  ÷ºÎÆÄÀÏ ¡¾¡¿¢¬©÷3.png    


 
 
 
*ÀÌÀü±Û K-GMP[(ÁÖ)Çѱ¹Áö¿¥ÇÇ] FSMA:Many people are unfamiliar with the requirements and consequences of fail
*´ÙÀ½±Û K-GMP[(ÁÖ)Çѱ¹Áö¿¥ÇÇ]_2014³â 10¿ù ¼Ò½ÄÁö